Discogen

Discogen is a medical technology company focused on developing non-invasive, ultrasound-based treatments for discogenic back pain. Its lead technology, the DiscRx™ system, utilizes targeted ultrasound to reduce inflammation and promote biological repair processes within the intervertebral disc. The company's approach aims to provide symptomatic relief and address the underlying pathophysiology of disc degeneration at a lower cost than traditional surgical interventions. Discogen is currently validating its proprietary technology in a First-In-Human clinical trial at Columbia University Irving Medical Center. The company's scientific foundation is built on research from leading institutions, including UCSF.